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The application of blood-borne gene therapy protocols to the brain is limited by the presence of the blood-brain barrier (BBB).
Viruseshavebeenextensivelyusedasgenedeliverysystems.However,theireﬃcacyinbrainislimitedbythelackoftransportacross
the BBB following intravenous (IV) administration. Recent progress in the “Trojan Horse Liposome” (THL) technology applied to
transvascular non-viral gene therapy of the brain presents a promising solution to the trans-vascular brain gene delivery problem.
THLs are comprised of immunoliposomes carrying nonviral gene expression plasmids. The tissue target speciﬁcity of the THL is
provided by peptidomimetic monoclonal antibody (MAb) component of the THL, which binds to speciﬁc endogenous receptors
located on both the BBB and on brain cellular membranes, for example, insulin receptor and transferrin receptor. These MAbs
mediate(a)receptor-mediatedtranscytosisoftheTHLcomplexthroughtheBBB,(b)endocytosisintobraincellsand(c)transport
to the brain cell nuclear compartment. The expression of the transgene in brain may be restricted using tissue/cell speciﬁc gene
promoters.ThismanuscriptpresentsanoverviewontheTHLtransporttechnologyappliedtobraindisorders,includinglysosomal
storage disorders and Parkinson’s disease.
1.Introduction
DNA-based therapeutics may become a new generation of
drugs for the treatment of brain disorders provided that the
problem of its delivery across the blood-brain barrier (BBB)
and into brain cells is solved. A global distribution of the
transgene throughout the brain is needed for most of the
enzyme replacement therapy protocols, and this could be
possible by the transvascular route to brain via transport
across the BBB. However, in the absence of either facilitated
or receptor mediated transport systems, only lipophilic mol-
ecules of less than 400Da are able to cross the BBB by
simple diﬀusion [1]. Naked DNA molecules are not trans-
ported through this barrier [2–4]. Viruses have been used
as brain DNA delivery systems with disappointing re-
sults associated with preexisting immunity, immunological
response induced by viral coat proteins, and inﬂammation
that led to demyelination [5–15]. Cationic lipids are widely
used for transfection of DNA in in vitro tissue culture
models. However, cationic lipid-DNA complexes in vivo are
unstable or form large molecular weight aggregates that de-
posit in the pulmonary vascular bed [16–18], which de-
creases its bioavailability for delivery to the brain.
An alternative approach for DNA delivery to the central
nervous system (CNS) is the “Trojan horse liposome” (THL)
technology [3, 4, 19–23]( Figure 1(a)). The construction of
THLs has been optimized for plasmid DNA encapsulation
[19]. The encapsulation of the transgene in the interior of
a liposome protects the coding DNA against degradation by
ubiquitous nucleases. Any DNA not fully encapsulated in the
interior of the THL is removed by treatment of the THL with
amixtureofexo/endonucleases.TheTHLisconstructedwith
polyethylene glycol- (PEG-) conjugated lipids, and the PEG
strands on the surface of the THL stabilizes the liposome in
vivoandincreasestheplasmaresidencetime[24,25].Asmall
fraction of the PEG molecules, that is, 1-2%, carry a terminal
maleimide functional group to allow for conjugation of
the liposome surface with thiolated targeting ligands. The
targeting ligand acts as a molecular Trojan horse (MTH) and
is directed at an endogenous BBB receptor/transporter, such2 Journal of Drug Delivery
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Figure 1: Engineering of Trojan horse liposomes (THL). (a) A supercoiled plasmid DNA is encapsulated in the interior of the THL. The
plasmid encodes for a coding sequence (cds), the expression of which is under the inﬂuence of a promoter (pro), that is, SV40, and a
polyadenylation sequence (pA). The surface of the liposome contains several thousand strands of 2000Da polyethylene glycol (PEG) to
stabilize the complex in blood. Approximately 1-2% of the PEG strands are conjugated with a targeting receptor- (R-) speciﬁc monoclonal
antibody (MAb) (Table 1), which triggers transport of the THL across biological barriers in vivo. THLs are engineered with a single type
of MAb to target both the BBB and brain cells in the same species. In an experimental mouse model of a human brain tumor, the THL
is engineered with both the 8D3 mouse transferrin receptor (TfR) MAb (MAb1) to target the mouse BBB (i.e., R1) and the 8314 human
IR MAb (MAb2) to target the human tumor cells (i.e., R2). Thus, the THL is transported through the mouse BBB via receptor-mediated
transcytosis on the mouse TfR, and then through the intracranial human glioma cell membrane via endocytosis on the human insulin
receptor. (b) Transmission electron microscopy of a THL. Mouse IgG molecules tethered to the tips of the PEG strands on the surface of the
THL were detected with a conjugate of 10nm gold and an antimouse secondary antibody. The position of the gold particles illustrates the
relationshipofthePEG-extendedMAbandtheliposomesurface.Magniﬁcationbar =20nm.(c)The3-barriermodelforgenetherapyofthe
brain. Following intravenous injection, the THL carrying the transgene must traverse 3 barriers in series to be able to reach the nucleus for
expression: (a) the blood-brain barrier (BBB), (b) the brain cell membrane (BCM), and (c) the nuclear membrane. THLs can be engineered
with a single type of MAb to target the same receptor in both the BBB and BCM (R1) or with 2 diﬀe r e n tM A b st ot a r g e td i ﬀerent receptors
at the BBB and the BCM, for example, R1 and R2, respectively. From [4].
as the insulin receptor (IR) or transferrin receptor (TfR)
receptor (Table 1)[ 3, 4, 19–23]. Widely used MTHs included
peptidomimetic monoclonal antibodies (MAb) against BBB
receptors. The extension of the PEG-conjugated MAb from
the surface of the THL is illustrated by electron microscopy
(Figure 1(b)).TheIRorTfRarealsoexpressedontheplasma
membrane of brain cells, which enables the THL to traverse
the brain cell membrane following delivery across the BBB
(Figure 1(c)). MAbs against the IR or TfR are almost always
species speciﬁc, and a MAb against the mouse TfR will
not recognize the TfR on human cells. Therefore, in mixed
animal models such as a brain tumor model produced by
the intracranial growth of a human glioma in the mouse,
a combination of targeting MAbs is used, so that the THL
is targeted across both the mouse BBB and the human
tumor cell membrane. For example, THLs were constructed
with a MAb to the mouse TfR, to target the THL complex
across the mouse BBB, and with a second MAb against the
human insulin receptor (HIR), to target the THL across an
intracranial human U87 glioma, as illustrated in Figure 1(a)
[23]. With the development of genetically engineered forms
of the HIRMAb, the THL technology may be translated to
humans [26]. The engineering of plasmid DNA encoding
the therapeutic transgene under the inﬂuence of brain cell-
speciﬁc promoters eliminates ectopic transgene expression
and enables transgene expression in targeted regions of the
CNS [2, 19–23, 27, 28].
2 .T r ojanH o rs eL ipo s o m e(T HL )T ec h n o l ogy
THLs are pegylated liposomes containing a supercoiled
plasmid DNA molecule in the interior of the liposome
(Figure 1(a)). THLs are engineered with a mixture of nat-
urally occurring lipids that has been optimized for the en-
capsulation of plasmid DNA [4, 19]. The liposomes are
comprised of 93% 1-palmitoyl-2-oleoyl-sn-glycerol-3-phos-
phocholine(POPC),3%didodecyldimethylammoniumbro-
mide (DDAB), 3% distearoylphosphatidylethanolamine
(DSPE)-PEG2000, and 1% DSPE-PEG2000-maleimide. The
maleimide functional group allows for covalent conjugation
of a thiolated MAb via a stable thioether linkage (Figure 1(a)
and Table 1). A panel of species-speciﬁc peptidomimeticJournal of Drug Delivery 3
Table 1: Targeting MAbs for THL and target tissue.
Targeting MAb Target receptor Experimental model and target tissue
Murine OX26 [53]R a t T f R
(a) Rat C6 or RG2 glioma in culture
(b) Rat C6-790 in cultures
(c) In vivo transport via rat BBB and rat brain cells (neuron and glial). Gene
delivery
Rat 8D3 [54] Mouse TfR In vivo transport via rat BBB and rat brain cells (neuron and glial). Gene delivery
Murine 8314 [60]H u m a n I R
(a) Human U87 glioma cultures
(b) In vivo transport via primate/human BBB and brain cells (neuron and glial).
Gene delivery
8D3 + 8314 [23] Mouse TfR + human IR
(a) Experimental human brain tumors in scid mice
(b) In vivo transport via mouse BBB and brain primate/human cells (neuron and
glial). Gene delivery
Chimeric anti-TfR [55] Mouse TfR Gene delivery in mice
Humanized anti-IR [26] Human IR Gene delivery in humans
MAbs has been developed (Table 1), and their eﬃcacy in
delivering THLs to brain has been demonstrated in exper-
imental animal models in vivo [1, 3, 4, 19–23, 27]. The
83-14 murine MAb to the HIR and the OX26 murine MAb
to the rat TfR are used to target human and rat tissues,
respectively (Table 1). The OX26 TfRMAb is active only in
rats, so the rat 8D3 MAb against the mouse TfR is used
in mice (Table 1)[ 20, 21, 27–33]. The 83-14 HIRMAb
does not cross-react with the insulin receptor in rodents
or even New World primates such as the squirrel monkey.
However, this HIRMAb does cross-react with the insulin
receptor of Old World primates such as the Rhesus monkey.
Since the plasmid DNA must be delivered to the nuclear
compartment of brain cells, the THL must traverse both the
BBB and the brain cell plasma membrane (BCM) behind the
BBB (Figure 1(c)). Owing to high expression of the TfR or
IR on both the BBB and BCM barriers, the targeting MAb
enables the sequential receptor-mediated transcytosis of
the THL across the BBB followed by the receptor-mediated
endocytosis of the THL into the brain cell (Figure 1(c)).
THLs have also been successfully constructed to target hu-
man tumor cells in a scid mouse model wherein dual tar-
geting MAbs were directed to the mouse TfR and HIR
(Table 1 and Figure 1(a), i.e., MAb1 and MAb2) [23].
3. Brain Expressionof Reporter Genes
In vivo applications of THLs were initially investigated with
luciferase and lacZ reporter genes in vivo [3, 4, 20, 21,
34]. THLs were constructed with the expression plasmid of
interest (i.e., luciferase reporter gene) and engineered with
either the TfRMAb for rodents or the HIRMAb for Rhesus
monkeys, respectively. The doses of DNA encapsulated in
THLs and administered IV was 5 or 70μgp e rr a to rp r i m a t e ,
respectively, which are equivalent 20 and 12μg/kg body
weight, respectively. When the transgene is driven by the
widely read SV40 promoter, the levels of luciferase were
∼10pg luciferase/mg protein in the monkey brain. High
levels of expression were also seen in peripheral tissues
that are rich in the target receptor, including liver, spleen,
and lung [27, 34]. A 50-fold increase in the tissue levels
of luciferase was reported in primates, as compared to rat
and mouse tissues. The high levels of expression in mon-
key tissues were associated with intrinsic properties of the
HIRMAb that targets the nuclear compartment of the cell
[4].
Time course studies in both rodents and primates dem-
onstrated that the peak of luciferase expression occurs 48hs
following injection of a single IV dose of THLs. The levels
of luciferase activity decline thereafter and as a function of
time. There are 2 potential mechanisms for the decline in the
expression of the transgene, that is, promoter inactivation
and plasmid degradation. The levels of both luciferase
enzymeactivityandplasmidDNAdecayintheprimatebrain
and liver were measured, and both processes decayed with a t
1/2 ofapproximately2days,whichindicatesthatthetransient
duration of the luciferase gene expression is mainly due to
plasmid degradation [33].
The organ distribution of the lacZ transgene was also
investigated at the cellular level with histochemistry follow-
ing THL delivery of a reporter gene driven by the SV40 pro-
moter and designated SV40-lacZ [4, 20, 34]. The latter was
used to engineer THLs with either the TfRMAb or the
HIRMAb (Table 1). The histochemical detection of the β-
galactosidase is shown in Figure 2 for the mouse and the
Rhesus monkey. The expression of the transgene was widely
detected through the cortical and subcortical structures of
mouse and monkey brain, with a greater gene expression in
gray matter relative to white matter in both cerebrum and
cerebellum (Figure 2). On the contrary, the β-galactosidase
histochemistry of control uninjected primate brain shows no
β-galactosidase activity (Figure 2(b)). Light micrographs of
the primate brain shows gene expression within the choroid
plexus epithelium (Figure 2(d)) and the capillary endothe-
lium within white matter (Figure 2(f)). The gene expression
was also conﬁrmed within the neurons of the occipital cortex
showing the columnar organization of this region in primate
brain (Figure 2(e)). The molecular and granular layers of
the cerebellum and the Purkinje cells were also positive
for the transgene (Figure 2(f)). Confocal microscopy studies
with antibodies against either bacterial β-galactoside or the
neuronal neuN marker colocalized transgene expression in4 Journal of Drug Delivery
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Figure 2: In vivo gene expression of a β-galactosidase reporter gene following systemic administration of THLs. (Top panels) β-galactoside
histochemistry was performed on mouse brain and spleen removed 2 days after an IV injection of THLs carrying a β-galactosidase plasmid
driven by either the SV40 promoter (SV40-lacZ-THL) (left panels) or Gfap promoter (Gfap-lacZ-THL) (right panels). THLs were targeted
with the 8D3 antimouse TfRMAb. (Bottom panels) β-Galactosidase histochemistry of Rhesus monkey brain removed from either a monkey
injected with THLs targeted with the HIRMAb ((a),(c), (d), (e), and (f))or a control uninjected primate (b). Theβ-galactosidase expression
plasmid is driven by the SV40 promoter. (a) shows a full coronal section of the primate forebrain. (c) shows half-coronal sections through
the primate cerebrum and a full coronal section through the cerebellum; the sections from top to bottom are taken from the rostral to
caudal parts of brain. (d, e, and f) are light micrographs of choroid plexus, occipital cortex, and cerebellum, respectively. All specimens are
β-galactosidase histochemistry without counterstaining. The magniﬁcation in (a) and (b) is the same and the magniﬁcation bar in (a) is
3mm; the magniﬁcation bar in (c) is 8mm; the magniﬁcation bars in (d)–(f) are 155μm. Top panels are from [21]. Bottom panels are from
[34].
the neuronal compartment of brain [27, 34]. The ectopic
expression of the β-galactosidase with the SV40-lacZ vector
was also observed in tissues expressing either the TfR or the
IR, such as spleen, providing that the transgene was driven
by the widely read SV40 promoter (Figure 2, top left panel).
It is possible to produce THLs that carry plasmid DNA
engineered with a tissue-speciﬁc promoter [20]. This is
of particular relevance in gene therapy protocols wherein
ectopic expression of the transgene is not desired. When the
lacZ expression plasmid is driven by the brain-speciﬁc pro-
moter derived from the 5 -ﬂanking sequence of the glial
ﬁbrillary acid protein (Gfap) gene, the expression of β-galac-
tosidase in brain was widely detected (Figure 2,t o pr i g h t
panel), as previously seen with the SV40-lacZ plasmid
(Figure 2, top left panel). On the contrary, there was no ex-
pression of the transgene in peripheral tissues (Figure 2,
bottom right panel) when the transgene was under the in-
ﬂuence of the brain-speciﬁc Gfap promoter. Tissue-speciﬁc
gene expression with the combined use of THLs and the
opsin promoter was demonstrated in vivo in the Rhesus
monkey [35].
4.InVivoEfﬁcacyof THLsin
aModel of Mucopolysaccharidosis
The in vivo eﬃcacy of THLs was investigated in a model
of type VII mucopolysaccharidosis (MPS), which is caused
by mutations in the gene encoding the lysosomal enzyme
β-glucuronidase (GUSB) [36]. MPS is a lysosomal storage
disorder, and the majority of lysosomal storage disorders
adversely aﬀect the central nervous system [37]. Therefore,
therapeutic transgenes must be delivered to all parts of the
brain, and this is only possible with a transvascular route to
brain.THLswerepreparedwithaplasmidDNAencodingforJournal of Drug Delivery 5
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Figure 3:EnzymereplacementtherapywithTHLsinamousemodeloftypeVIImucopolysaccharidosis.(a)GUSBenzymeactivityinGUSB
null (−) ﬁbroblasts and in ﬁbroblasts obtained from wild type (+) mice. Fibroblasts were treated either with saline or with TfRMAb-targeted
THLs encapsulated with the pCMV-GUSB expression plasmid. Data are mean ± SE (n = 4), and statistical signiﬁcance was determined with
ANOVA and Dunnett’s test. The diﬀerence in GUSB enzyme activity in the THL-treated cells is signiﬁcantly diﬀerent from the untreated
cells from the GUSB null mice (P<0.01). (b) GUSB enzyme activity in brain and ﬁve other organs of GUSB null mice removed at 48h after
single intravenous administration of either saline or 10ug/mouse of pCMV-GUSB plasmid DNA encapsulated in TfRMAb-targeted THLs.
Mean ± SE (n = 4-5 mice/group). The diﬀerence in GUSB enzyme activity in the THL-treated mice, as compared to the saline-treated mice,
is signiﬁcant (P<0.0005), in all organs, except the heart. From [36].
GUSB, and with the TfRMab to target THLs across both the
BBB and the BCM in a transgenic mouse model of MPS-VII.
The GUSB expression plasmid, designated pCMV-GUSB, is
driven by the widely read cytomegalovirus (CMV) promoter.
The latter was preferred over a brain-speciﬁc promoter, as
MPS-VII aﬀects both the CNS and peripheral tissues. The
GUSB enzyme activity was investigated in cultured ﬁbrob-
lasts obtained from GUSB null mice [GUSB(−)], and >50-
fold increase in the GUSB activity was observed following
incubation with the THL carrying the pCMV-GUSB as
compared with control GUSB(−) ﬁbroblasts (Figure 3(a)).
The GUSB enzyme activity persisted at high levels for over
2-week period [36].
In vivo studies in GUSB null mice were also performed
with a single dose of 10ug/mouse of pCMV-GUSB encapsu-
lated in TfRMAb-targeted THLs. The GUSB enzyme activity
in brain and peripheral organs was determined 48 hours
after IV injection. GUSB enzyme activity was increased >10-
fold in brain, liver, spleen, lung, and kidney, but not in
heart (Figure 3(b)). The expression pattern of GUSB gene
among mouse organs in vivo is consistent with the local
expression of the TfR in the vascular barriers of these tissues.
The liver and spleen are perfused with fenestrated capillaries
that are highly porous, so the 100nm THLs can freely
cross their vascular barrier [20]. Heart, lung, and kidney
are perfused with capillaries with continuous endothelial
barriers [38]. Thus, the observation that GUSB enzyme
activity is increased in lung and kidney with TfRMAb-
targeted THLs in vivo provides additional evidence for the
expression of the TfR on the vascular barrier in these organs
in the mouse [27]. Lack of expression in heart supports prior
work with reporter genes showing that TfRMAb-targeted
THLs are not delivered across the vascular barrier in heart
[20, 21, 27]. The brain GUSB enzyme activity observed
at 48h after a single THL administration approximated
2U/mgprotein(Figure 3(b)), which represents 55% of the
brain level in heterozygotes [39]. Since the replacement of
just 1–5% of lysosomal enzyme activity in an organ may
be suﬃcient to cause therapeutic eﬀects and a reversal of
lysosomal storage disease [37], the levels of GUSB enzyme
activity generated in the brain of null mice with a single
IV injection of THLs is within the therapeutic range. The
plasmid DNA is expressed episomally in brain cells without
integration into the host genome [33]. Therefore, long-term
treatment of lysosomal storage disorders with intravenous
administration of THLs will require repeat administration of
the gene medicine at intervals that are determined by both
the persistence of transgene expression and the turnover of
the expressed protein in brain and peripheral organs.
5. Brain Expression of Therapeutic Genes in
a Model of Parkinson’sDisease
ThetherapeuticeﬃcacyofTHLswasdemonstratedinvivoin
a model of Parkinson’s disease (PD), wherein the therapeutic
gene encoded for tyrosine hydroxylase (TH) [30]. PD is
associated with a loss of dopaminergic neurons in the sub-
stantia nigra, which terminate in the striatum [40, 41]. The
rate limiting enzyme in the synthesis of dopamine is TH, and
apotentialtreatmentforPDisTHgenereplacementtherapy.
Studies were performed in the rat 6-hydroxydopamine
(6-OHDA) model, and with THL packaged with a TH
expression plasmid driven by the Gfap brain-speciﬁc pro-
moter, designated clone 951 [30]. Gfap-TH-THLs were
constructed with the OX26 MAb to target the rat TfR
(Table 1). The intracerebral injection of 6-OHDA produced
a 98% reduction in the levels of TH in the ipsilateral stri-
atum as compared with the contralateral or nonlesioned6 Journal of Drug Delivery
Table 2: Tyrosine hydroxylase (TH) in brain and peripheral organs in the rat 3 days after intravenous injection of gene therapy with TH
expression plasmids driven by either the SV40 promoter (clone 877) or the Gfap promoter (clone 951), respectively.
Organs Saline (pmol/hr/mgp) TfRMAb-THL/877 (pmol/hr/mgp) TfRMAb-THL/951 (pmol/hr/mgp)
Ipsilateral striatum 128 ± 27 5177 ± 446∗ 5536 ± 395∗
Contralateral striatum 6445 ± 523 5832 ± 391 5713 ± 577
Ipsilateral cortex 176 ± 30 132 ± 16 184 ± 38
Contralateral cortex 150 ± 36 150 ± 24 135 ± 25
Heart 29 ± 34 5 ± 83 1 ± 3
Liver 13 ± 2 130 ± 28∗∗ 18 ± 6
Lung 42 ± 13 74 ± 22 30 ± 6
Kidney 24 ± 23 5 ± 53 1 ± 8
∗P<0.01 diﬀerence from saline group (ANOVA with Bonferroni correction; n = 4 rats per group). Rats were lesioned with intracerebral injections of 6-
hydroxydopamine; 3 weeks after toxin injection, the rats were tested for apomorphine-induced rotation behavior; those rats testing positively to apomorphine
were selected for gene therapy, which was administered intravenously 4 weeks after toxin administration; all animals were euthanized 3 days after gene
administration. From [30].
control animals (Table 2). Animals with positive lesion were
identiﬁed by apomorphine-induced contralateral rotation
and administered 10μg clone 951 DNA encapsulated in
either OX26-THL or in THLs targeted with a non-speciﬁc
isotype control IgG1a mouse IgG, as a negative control [30].
The apomorphine-induced contralateral rotation test was
used to demonstrate therapeutic eﬃcacy. In the negative
controlgroupadministeredwiththe951-THLstargetedwith
the non-speciﬁc IgG2a, the drug-induced rotation increased
in all animals [30]. On the contrary, in the rats injected with
the 951-THLs targeted with the TfRMAb, there was an 82%
reduction in the apomorphine-induced contralateral rota-
tions[30].ThetherapeuticeﬀectoftheTHgenereplacement
was correlated with the levels of TH determined by enzyme
activity (Table 2) or immunocytochemistry (Figure 4). The
latterwasperformedin coronalsections of brainandshowed
complete normalization of the immunoreactive TH in the
striatum of 6-OHDA lesioned rats 3 days after a single
injectionofthegenetherapy(Figures4(a)–4(c)).Incontrast,
lesioned control animals treated with the THLs targeted
with the non-speciﬁc IgG2a isotype control antibody show
a marked reduction in striatal immunoreactive TH (Figures
4(d)–4(f)). The levels of the TH enzyme activity were also
normalized in the ipsilateral striatum (Table 2). Additional
studies were performed in the 6-OHDA PD rat model with
THLs carrying the TH gene under the widely read SV40
promoter, that is, clone 877 (Table 2)[ 22]. Similar data
were obtained in both the restoration of the TH expression
p a t t e r ni nb r a i na n di nt h er e d u c t i o no ft h ea p o m o r p h i n e -
induced contralateral rotation [22]. The only diﬀerence
between the studies performed with the TH expression
plasmid driven by the SV40 promoter, or the Gfap promoter,
was a 10-fold increase in the levels of TH activity in liver
of animals injected with the SV40-TH construct, which is
not seen with the Gfap-TH plasmid (Table 2 and Figure 2).
The stability of the TH is associated with the availability
of the biopterin cofactor, and the expression of the TH
enzyme is found in regions of the brain that express GTP
cyclohydrolase 1 (GTPCH) [42–44]. The GTPCH is also
expressedinperipheraltissues,likeliver[45],whichsupports
the increased expression in liver TH activity when the TH
transgene is driven by the SV40 promoter (Table 2)[ 22].
The gene therapy in this PD model with either SV40- or
Gfap-THplasmidsproducednormalizationoftheexpression
pattern of TH and without expression of supranormal levels
of TH activity (Table 2)[ 22, 30]. This observation parallels
ﬁndings observed in TH transgenic mice, which showed only
aminorincreaseineitherimmunoreactiveTHorTHactivity
in striatum despite a 50-fold increase in the level of TH
mRNAinthesubstantianigra[46].Thelatter,inconjunction
with the TH gene therapy with THLs (Table 2 and Figure 4),
suggests that the expression of the TH gene is regulated at
the posttranscriptional level in brain, so that the striatal TH
activity is maintained within a narrow range [47]a n db y
neurons expressing the GTPCH cofactor gene.
As discussed above for the GUSB gene therapy, the
plasmid DNA in THL is not integrated into the host genome
[33]. Therefore, long-term treatments with repetitive intra-
venous administration of THLs are needed to produce a
long-term therapeutic eﬀect. The engineering of plasmid
DNA vectors that incorporate intronic or chromosomal-
derived gene elements may produce more sustained expres-
sion of the transgene following THL delivery. Therefore, a
TH expression plasmid was engineered which incorporated
the TH gene [48]. A series of 4 rat TH expression plasmids,
designated clone 877, prgTH2, prgTH3, and prgTH4, were
derived from the rat TH gene or cDNA, as outlined in
Figure 5(a). Clone 877 is comprised of the TH cDNA driven
by the SV40 promoter. Clone prgTH2 encodes a 12kbTH
genomic expression cassette, which includes a 3.0kb TH
5 -ﬂanking sequence (FS), the 7.3kb rat TH coding region,
and a 1.9kb 3 -FS. The 3kb rat TH 5 -FS in prgTH2 was
expanded to 8.4kb with the engineering of clone prgTH3.
The introns and 3 -FS were eliminated by engineering clone
prgTH4 (Figure 5(a)).
The cDNA form of TH gene therapy, clone 877, caused
a 26-fold increase in striatal TH enzyme activity at 3 days
after the IV injection, but this declined over 12-fold by 10
days (Table 3). There was a signiﬁcant 86% improvement
in motor function at 3 days after the injection of clone
877, but this improvement was not signiﬁcant at 6 and 10
days after the single IV injection (Table 3). The genomicJournal of Drug Delivery 7
(a) (b) (c)
(d) (e) (f)
Figure 4: Levels of TH in brain following TH-gene therapy in the 6-OHDA Parkinson’s disease model. The TH immunocytochemistry was
performed in rat brains removed 72 hours after a single intravenous injection of 10μg per rat of clone 951 plasmid DNA encapsulated in
THL targeted with either the TfRMAb (a, b, and c) or with the mouse IgG2a isotype control (d, e, and f). Coronal sections are shown for
3d i ﬀerent rats from each of the two treatment groups. The 6-hydroxydopamine was injected in the medial forebrain bundle of the right
hemisphere, which corresponds to right side of the ﬁgure. Sections are not counterstained. The animals that received the TH gene therapy
had a normalization of the brain TH levels as compared to the animals administered the nontargeted THLs, which showed complete lost of
immunoreactive TH in the same region. From [30].
TH expression plasmids produced in general a lower peak
of striatal TH enzyme activity in vivo, but a more lasting
therapeutic eﬀect. Striatal TH enzyme activity at 3 days
after IV injection of prgTH2, or prgTH4, was less than that
observed with clone 877, but the striatal TH enzyme activity
at 10 days after injection with prgTH2 was signiﬁcantly
higher than with clone 877 (Table 3). The IV administration
of prgTH3 resulted in no signiﬁcant increase in striatal
TH enzyme activity at 3 or 6 days after administration,
relative to clone 877 or prgTH2, but yielded the highest
striatal TH enzyme activity, and the lowest drug-induced
rotation, of any single therapy at 10 days afteradministration
(Table 3). Therefore, the clone 877 cDNA form of TH
gene therapy is fast acting with short duration, whereas
the genomic form of TH gene therapy with prgTH3 is
slow acting with long duration (Table 3). The combination
cDNA/genomic TH gene therapy was further investigated
with THLs carrying both 877 and prgTH3 plasmids (Fig-
ures 5(b) and 5(c)). The striatal TH enzyme activity was
signiﬁcantly higher with the combination gene therapy as
compared to clone 877 alone at 10 days after injection, and
it was signiﬁcantly higher as compared to prgTH3 alone at
3 and 6 days after injection (Figure 5(b)). The combination
therapy also produced a parallel reduction in apomorphine
rotation behavior (Figure 5(c)). The rotation behavior was
signiﬁcantly reduced with combination gene therapy as
compared to clone 877 alone at 10 days after injection, and it
was signiﬁcantly reduced as compared to prgTH3 alone at 3
days after injection.
In summary, combination gene therapy is superior to
single cDNA gene therapy. The combination gene therapy
using both short-acting cDNA-derived TH transgene and
long-acting genomic-derived TH transgene provides a more
sustained therapeutic duration in experimental PD as com-
pared to single gene therapy using either cDNA-derived or
genomic-derived transgene
6. Long-Term Treatment withTHL
Plasmid DNA-based gene therapy with THL technology
involves episomal gene expression and must be given on a
chronic basis, which raises concerns about potential toxic
side eﬀects from chronic repeat THL dosing. A 6-week tox-
icological study was conducted with repeated weekly intra-
venous administration of THLs carrying a 7 kb expression
plasmid encoding for rat TH and targeted with either
the OX26 MAb to the rat TfR or with the mouse IgG2a
isotype control antibody [49]. Animals were divided into 3
treatment groups: (a) saline, (b) 5ug DNA/week of the THLs
targeted with the TfRMAb, and (c) 5ug DNA/week of the
THLs targeted with the nonspeciﬁc isotype control IgG2a
antibody. At the end of 6 weeks of chronic weekly treatment,
there was no measurable diﬀerences in the 3 groups with
respect to body weights, 14 serum chemistries (Table 4),
or organ histology of brain, liver, spleen, kidney, heart,
or lung. The immunocytochemistry showed no evidence
of inﬂammation in brain using antibodies that react with
multiple components of the immune system [49]. These
results demonstrate the lack of toxicity of chronic dosing of
MAb-targeted THLs carrying plasmid DNA
7. Formulation of THL
The eﬃciency of gene delivery to the brain and gene ex-
pression in target cells with THLs may be potentially
enhanced by optimizing the formulation of THLs. The
use of ethanol-mediated DNA condensation was recently8 Journal of Drug Delivery
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Figure 5: Enzyme replacement therapy in a Parkinson’s disease model using THLs and TH genomic expression vectors. (a) Diagrams of
four rat TH expression plasmids. The poly(A) transcription termination sequence is the SV40 3 -untranslated region (UTR) derived from
the pGL2 promoter vector (Promega) for both clone 877 and prgTH4, whereas the poly(A) signal for prgTH2 and prgTH3 is derived from
the rat TH gene. (b) Striatal TH enzyme activity on the side ipsilateral to the toxin lesion at 3, 6, and 10 days after a single injection of either
saline or THLs carrying clone 877 alone, prgTH3 alone, or clone 877 + prgTH3 combined. Data are mean ± S.E. (n = 3–6 rats per point),
and statistically signiﬁcant diﬀerences were determined by Student’s t-test. All plasmids were delivered to rat brain following the intravenous
injection of TfRMAb-targeted THLs. The TH activity at 3 days following combination therapy is signiﬁcantly greater than prgTH3 alone at
3 and 6 days after injection (P<0.005) and is greater than clone 877 alone at 10 days after injection (P<0.005). (c) Apomorphine-induced
rotations at 3, 6, and 10 days after a single injection of either saline or THLs carrying clone 877 alone, prgTH3 alone, or clone 877 + prgTH3
combined. Data are mean ± S.E. (n = 3–6 rats per point). The rotation behavior at 3 days following combination therapy is signiﬁcantly
reduced as compared to prgTH3 alone at 3 days after injection (P<0.005) and is signiﬁcantly reduced as compared to clone 877 alone at 10
days after injection (P<0.005). From [48].
shown to increase the eﬃciency of DNA encapsulation in
THLs [50], and the polymer polyethylenimine (PEI) allowed
for encapsulation of PEI/oligodeoxynucleotide polyplexes
in THLs [51]. Avidin-biotin technology may also facilitate
conjugation of ligands to THLs [52]. MAbs directed to the
mouse or rat TfR and the human HIR are the most potent
BBB Trojan horses developed to date for drug delivery across
the mouse, rat, or primate BBB, respectively [26, 53–55],
and the THL technology has been validated in numerous
animalsmodels (seeabove).Asnewtargetingmoleculeswith
increased brain uptake, as compared to TfR- and HIR-MAb,
become available, it may also be possible to engineer THLs
with improved brain uptake and therapeutic eﬃcacy.
Other ligands have been tested in the construction of
DNA liposomes, but demonstrated limitations in terms
of speciﬁcity and/or global distribution of the transgeneJournal of Drug Delivery 9
Table 3: Tyrosine hydroxylase (TH) in brain and apomorphine-induced contralateral rotation after intravenous injection of gene therapy
with TH expression plasmids.
Treatment (group) Days after Rx Apomorphine revolutions before Rx Apomorphine revolutions after Rx Striatal TH (pmol/h/mgp)
Saline
3 324 ± 69∗ 401 ± 72 162 ± 36
6 232 ± 43 342 ± 62 288 ± 42
10 228 ± 23 331 ± 55 120 ± 18
Clone 877
3 196 ± 24 56 ± 20b 4286 ± 918b
6 231 ± 47 230 ± 55 1015 ± 213a
10 219 ± 35 256 ± 27 335 ± 79a
prgTH2
3 251 ± 38 123 ± 31b 1343 ± 176b,c
6 295 ± 55 119 ± 34a 1535 ± 324b
10 344 ± 27 443 ± 70c 884 ± 7b,d
prgTH3
3 317 ± 23 234 ± 38d 167 ± 35d
6 197 ± 11 127 ± 11a 545 ± 117a
10 202 ± 31 111 ± 9b,d 985 ± 101b,d
prgTH4
3 211 ± 28 100 ± 9b 1219 ± 137b,c
6 234 ± 37 113 ± 20b 1621 ± 196b
10 3 ± 64 249 ± 64 500 ± 86b
None NA 0 0 5068 ± 168
Rx: single IV injection of TfRMAb-targeted THLs encapsulating the respective TH expression plasmid. ∗Mean ± S.E. (n = 3–6 rats per point). Statistically
signiﬁcant diﬀerences were determined by Student’s t-test.
Clone 877 is the TH expression plasmid driven by the SV40 promoter. For details in the engineering of TH genomic vectors, clones prgTH2–TH4, please see
Figure 5.
Diﬀerence with saline: P<0.05a; P<0.005b.
Diﬀerence with clone 877: P<0.05c; P<0.005d.
NA: not applicable.
From [48].
Table 4: Summary of serum chemistry in long-term treatment with THLs.
Assay Units Saline mIgG2a-PIL OX26-PIL
Sodium mM 143 ± 1 142 ± 1 140 ± 1
Potassium mM 4.4 ± 0.1 4.6 ± 0.1 4.6 ± 0.2
Chloride mM 100 ± 1 100 ± 1 100 ± 1
CO2 mM 29 ± 12 9 ± 12 7 ± 1
Glucose mg/dL 168 ± 8 160 ± 6 163 ± 4
Creatinine mg/dL 0.45 ± 0.03 0.40 ± 0.01 0.45 ± 0.02
Urea nitrogen mg/dL 19 ± 12 1 ± 21 8 ± 1
Total protein g/dL 5.2 ± 0.1 5.3 ± 0.1 5.3 ± 0.1
Albumin g/dL 1.4 ± 0.1 1.4 ± 0.1 1.4 ± 0.1
Bilirubin, total mg/dL 0.35 ± 0.03 0.25 ± 0.05 0.33 ± 0.02
Alk phos U/L 231 ± 27 212 ± 25 281 ± 11
AST (SGOT) U/L 65 ± 55 9 ± 27 4 ± 6
ALT (SGPT) U/L 54 ± 25 2 ± 35 9 ± 1
Calcium mg/dL 9.4 ± 0.1 9.5 ± 0.2 9.2 ± 0.1
Data are mean ± SE (n = 6 rats in each of the three treatment groups). From [49].
in the brain. Tat-peptide-modiﬁed liposomes were able to
target human brain tumors in mice, but not the normal
brain adjacent to the tumor [56]. Immunoliposomes labeled
with anti-GFAP MAb targeted gliomas that had disruption
of the BBB, but they were unable to penetrate unimpaired
BBB [57]. Glycosylation of DNA lipoplexes and liposomes
have been proposed to increase biodistribution most likely
via absorptive endocytosis [58, 59]; however, the application
of these constructs to gene delivery to the brain remains to
be demonstrated.
8. Conclusions andFutureDirections
The THL plasmid DNA gene transfer technology has been
validatedinmultipleanimalmodelsinmice,rats,andRhesus
monkeys, and this work shows that it is possible to deliver10 Journal of Drug Delivery
transgenes to brain following the noninvasive intravenous
administrationofnonviralformulations.Theectopicexpres-
sion of the transgene is shown to be eliminated by the com-
bined use of THLs and plasmid DNA engineered with tissue-
speciﬁc gene promoters. Transgene expression following
THL delivery is reversible secondary to degradation of the
plasmid DNA, which is not integrated into the host genome.
This nonintegrating property of plasmid DNA is considered
advantageous, since the integration of viral genomes into the
host DNA can lead to insertional mutagenesis. Increase in
the duration of plasmid DNA expression is possible with the
engineeringofplasmidDNAthatincorporateschromosomal
elements.THLscanbeadministeredchronicallywithouttox-
icity or immune reactions
The THL technology can be translated to humans
with the use of human-speciﬁc antibodies that are genet-
ically engineered to reduce immunogenicity. The murine
HIRMAb, which is active at the human BBB, has been genet-
ically engineered, and a humanized HIRMAb has been pro-
duced[26].Therefore,itispossibletoproduceTHLswiththe
humanized HIRMAb for gene transfer to the human brain
(Table 1).
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